Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Axon Drugs

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Nature Aging Publishes Phase II Results for AADvac1, a First-in-Man Alzheimer's Tau Vaccine Developed by Axon Neuroscience

Contact the Supplier

Lead Product(s): AADvac1

Therapeutic Area: Neurology Product Name: AADvac1

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

Details:

AADvac1 vaccine demonstrates robust antibody response, excellent safety profile and highly significant impact on neurodegeneration in Alzheimer's disease.